Abstract
EBV-positive mucocutaneous ulcer （EBVMCU） was first proposed in 2010 by Dojcinov et al. as a series of EBV-positive ulcerative lesions on the mucosa of the oropharynx, skin, and gastrointestinal tract. It was newly classified as an independent group of diseases with good prognosis in the fourth edition of the WHO classification in 2017. In this article, we report three cases of oral mucosal ulcer diagnosed as EBVMCU and the treatment progress with a review of 25 patients reported in Japan.
Patient 1: A 75-year-old woman with an ulcer on the upper left gingiva of the molar region. She had been taking methotrexate （MTX） to treat her rheumatoid arthritis （RA）. Patient 2: A 67-year-old man with an ulcer on the lower left gingiva of the incisor region. He had been taking MTX to treat his RA. Patient 3: A 77-year-old woman with an ulcer on the upper right gingiva and palate of the incisor region. She had been taking MTX to treat her RA.
The clinical diagnosis was a suspected malignant tumor in two patients and severe oral mucositis in one patient, but a definitive diagnosis of EBVMCU was obtained by careful hearing of the medical history and biopsy in all three patients. They discontinued administration of MTX and the lesions disappeared.
